[A24-06] Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2024
Project no.:
A24-06
Commission:
Commission awarded on 10.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Children aged 5 to 11 years with homozygous familial hypercholesterolaemia in whom dietary and drug options for lipid lowering have been exhausted
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-06_en
| Project no. | Title | Status |
|---|---|---|
| A24-05 | Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |